Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Up - Here's What Happened

Key Points

• Bavarian Nordic shares gapped up premarket, opening at $9.725 vs. a prior close of $9.375 (about a 3.7% rise) on light trading volume of 793 shares.
• The company has a market cap of $2.31 billion and a P/E of 11.05; it reported an EPS of $(0.20) last quarter on $226.16 million in revenue, while analysts expect 0.67 EPS for the current fiscal year.
• Bavarian Nordic is a vaccine-focused biotech with approved commercial products including Jynneos (Imvamune/Imvanex), Rabipur and Encepur.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $9.3750, but opened at $9.7250. Bavarian Nordic shares last traded at $9.7250, with a volume of 793 shares traded.

Bavarian Nordic Trading Up 3.7%

The firm has a market cap of $2.31 billion, a P/E ratio of 11.05 and a beta of 1.34. The company's 50-day moving average is $10.06 and its two-hundred day moving average is $10.66.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.20) EPS for the quarter. Bavarian Nordic had a return on equity of 11.44% and a net margin of 22.20%.The company had revenue of $226.16 million for the quarter. Research analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.